Your browser doesn't support javascript.
loading
Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study.
Penovich, Patricia; Wheless, James W; Hogan, R Edward; Guerra, Cynthia; Cook, David F; Carrazana, Enrique; Rabinowicz, Adrian L.
Afiliação
  • Penovich P; Minnesota Epilepsy Group, 225 Smith Ave N, Suite 201, St. Paul, MN 55102, United States. Electronic address: ppenovich@mnepilepsy.net.
  • Wheless JW; Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Pediatric Neurology, 49 N Dunlap Ave, 3rd Floor - FOB, Memphis, TN 38105, United States.
  • Hogan RE; Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, United States.
  • Guerra C; Neurelis, Inc., 3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121, United States.
  • Cook DF; Neurelis, Inc., 3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121, United States.
  • Carrazana E; Neurelis, Inc., 3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121, United States.
  • Rabinowicz AL; Neurelis, Inc., 3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121, United States.
Epilepsy Behav ; 121(Pt A): 108013, 2021 08.
Article em En | MEDLINE | ID: mdl-34022621
BACKGROUND: Ideal rescue treatments for acute treatment of seizure clusters should be easy to administer, so it is important to assess user perceptions of these treatments. Diazepam nasal spray is designed to have a rapid, noninvasive, and socially acceptable route of administration. Patient and caregiver (including care partner) responses to surveys from a phase 3 safety study of diazepam nasal spray are reported. METHODS: The study enrolled patients aged 6-65 years with seizure clusters. Surveys distributed to patients and caregivers at study end, completion, or discontinuation collected data on comfort using diazepam nasal spray outside the home, timing of administration and return to their usual selves, and comfort of use compared with rectal diazepam. Safety was assessed. RESULTS: Of 175 patients enrolled at the October 31, 2019, interim cutoff, 158 received diazepam nasal spray. Sixty-seven (42.4%) patients and 84 (53.2%) caregivers responded to the surveys (including 35 matched pairs). Most patients (78.8%, 52/66) responded that they were very comfortable doing activities outside the home with diazepam nasal spray available; 59.4% of patients returned to their usual selves within an hour of administration. Twenty-seven (40.3%) of these patients reported self-administration, 48% doing so at the first sign of a seizure. Administration of diazepam nasal spray was rated extremely or very easy by 93.8% of caregivers. Safety profile was consistent with diazepam rectal gel; no patient discontinued owing to treatment-emergent adverse events. Nasal discomfort was typically mild and transient. Among patients who had used diazepam rectal gel, most were not at all comfortable using it outside the home (86.7%) or at home (64.5%) compared with diazepam nasal spray, whereas caregivers reported that diazepam rectal gel was not at all easy to use compared with diazepam nasal spray. CONCLUSIONS: This survey from the phase 3 safety study of diazepam nasal spray shows that patients and caregivers were satisfied with, and more comfortable using, diazepam nasal spray than rectal diazepam in public. NCT02721069.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidadores / Sprays Nasais Limite: Humans Idioma: En Revista: Epilepsy Behav Assunto da revista: CIENCIAS DO COMPORTAMENTO / NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidadores / Sprays Nasais Limite: Humans Idioma: En Revista: Epilepsy Behav Assunto da revista: CIENCIAS DO COMPORTAMENTO / NEUROLOGIA Ano de publicação: 2021 Tipo de documento: Article